Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Nancy A. Melville

    News

    Update Coming for Thyroid Disease in Pregnancy Guidelines

    Author:
    Nancy A. Melville
    Publish date: November 11, 2024

    Age over 30 years, having at least two prior pregnancies, and morbid obesity (body mass index [BMI] at least 40 kg/m2), will no longer...

    • Read More

    News

    Myeloma: Isa-KRd Induction Shows High MRD Responses

    Author:
    Nancy A. Melville
    Publish date: October 9, 2024

    Interim analysis of first MIDAS trial findings shows “highest rate of response and MRD negativity to date.”

    • Read More

    News

    Daratumumab Quadruplet Supported Transplant-Ineligible MM

    Author:
    Nancy A. Melville
    Publish date: October 3, 2024

    A phase-3 study showed that adding daratumumab to VRd yields a primary endpoint of MRD negativity in patients newly diagnosed with myeloma.

    • Read More

    News

    Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes

    Author:
    Nancy A. Melville
    Publish date: September 30, 2024

    New research shows that adding daratumumab to maintenance therapy improves MRD and PFS outcomes in multiple myeloma.

    • Read More

    News

    SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D

    Author:
    Nancy A. Melville
    Publish date: September 16, 2024

    Those receiving SGLT2i treatment had a 21% reduced risk for all-cause dementia and a 22% reduced risk for all-cause dementia and Parkinson’s...

    • Read More

    News

    After Rapid Weight Loss, Monitor Antiobesity Drug Dosing

    Author:
    Nancy A. Melville
    Publish date: August 15, 2024

    Toxicities from excessive doses can have a range of detrimental effects; examine dosing following rapid weight loss.

    • Read More

    News

    LBCL: CAR T Benefits Both Young and Old

    Author:
    Nancy A. Melville
    Publish date: July 26, 2024

    Evidence shows that CAR T-cell therapy yields similar survival outcomes for both older and younger patients with large B-cell lymphoma.

    • Read More

    News

    Hemophilia: Novel Tx Also Cuts Bleeding in Kids

    Author:
    Nancy A. Melville
    Publish date: July 22, 2024

    For pediatric patients with hemophilia A, once-weekly factor VIII prophylaxis shows bleeding protection similar to that for adults.

    • Read More

    News

    What Should Be Prioritized in Managing Early Diabetes?

    Author:
    Nancy A. Melville
    Publish date: July 3, 2024

    ADA meeting debate on what to treat first in early diabetes included obesity, glucose, remission as priorities.

    • Read More

    News

    Hemophilia: Marstacimab Sustains Long-Term Bleeding Reduction

    Author:
    Nancy A. Melville
    Publish date: June 26, 2024

    In an interim analysis, this novel, weekly subcutaneous injection shows continued benefits in the prevention of bleeding in hemophilia A and B.

    • Read More

    News

    Pancreatic Gene Therapy: A ‘One-and-Done’ GLP-1 Treatment?

    Author:
    Nancy A. Melville
    Publish date: June 26, 2024

    A single-dose pancreatic gene therapy may compare with GLP-1 effect, a mouse model study finds.

    • Read More

    News

    DLBCL: Glofitamab Plus Chemo Boosts Survival

    Author:
    Nancy A. Melville
    Publish date: June 20, 2024

    The bispecific antibody glofitamab, combined with chemotherapy, significantly improves overall survival in second-line treatment of DLBCL.

    • Read More

    News

    APL: Should Chemo-Free Regimen Become New Standard?

    Author:
    Nancy A. Melville
    Publish date: June 20, 2024

    Fresh data indicates that the benefits of a chemo-free regimen also extend to the treatment of high-risk acute promyelocytic leukemia.

    • Read More

    News

    Myeloma: First-In-Class ADC Regimen Yields Key Benefits

    Author:
    Nancy A. Melville
    Publish date: June 6, 2024

    Patients with relapsed/refractory multiple myeloma show significant improvements in PFS when treated with an antibody-drug conjugate.

    • Read More

    News

    CML: Asciminib Bests Standard TKIs as Frontline Therapy

    Author:
    Nancy A. Melville
    Publish date: June 3, 2024

    For CML, this potent, highly selective TKI significantly improves molecular responses, reduces discontinuations versus standard TKIs.

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery